Laurent Peyrin-Biroulet Selected Research

Mesalamine (Mesalazine)

1/2021	Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease.
1/2021	Incidence of and Risk Factors for Colorectal Strictures in Ulcerative Colitis: A Multicenter Study.
9/2020	Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis.
1/2020	Modern use of 5-aminosalicylic acid compounds for ulcerative colitis.
10/2019	Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.
2/2018	Colorectal cancer prevention in patients with ulcerative colitis.
7/2017	Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile.
1/2017	Is Mesalamine Effective for the Induction of Remission in Crohn's Disease?
1/2017	Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting.
1/2017	Ulcerative colitis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laurent Peyrin-Biroulet Research Topics

Disease

159	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 12/2022 - 10/2006
155	Crohn Disease (Crohn's Disease) 11/2022 - 09/2006
123	Ulcerative Colitis 12/2022 - 04/2007
41	Inflammation (Inflammations) 12/2022 - 10/2006
30	Infections 11/2022 - 10/2006
29	Necrosis 01/2022 - 07/2011
29	Neoplasms (Cancer) 01/2022 - 12/2006
23	Colitis 01/2021 - 04/2007
16	Rheumatoid Arthritis 06/2022 - 07/2009
13	Fistula 01/2022 - 09/2006
10	Psoriasis (Pustulosis Palmaris et Plantaris) 02/2022 - 05/2015
9	Pathologic Constriction (Stenosis) 01/2022 - 08/2010
9	Hemorrhage 01/2022 - 01/2019
8	Herpes Zoster 06/2022 - 08/2013
8	Disease Progression 01/2022 - 01/2010
7	Proctitis 11/2022 - 08/2008
7	Fibrosis (Cirrhosis) 11/2022 - 03/2006
7	COVID-19 06/2022 - 01/2020
6	Anemia 10/2022 - 12/2015
6	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 07/2013
6	Opportunistic Infections (Opportunistic Infection) 07/2021 - 09/2006
6	Sclerosing Cholangitis 11/2020 - 11/2006
5	Psoriatic Arthritis 02/2022 - 06/2017
5	Abscess 01/2022 - 09/2012
5	Multiple Sclerosis 01/2021 - 09/2006
4	Iron Deficiencies 10/2022 - 02/2016
4	Rheumatic Diseases (Rheumatism) 06/2022 - 06/2020
4	Ankylosing Spondylitis 02/2022 - 01/2012
4	Ulcer 01/2022 - 03/2015
4	Skin Neoplasms (Skin Cancer) 12/2020 - 01/2014
4	Carcinogenesis 12/2017 - 06/2004
3	Abdominal Pain (Pain, Abdominal) 10/2022 - 01/2022
3	Thrombosis (Thrombus) 06/2022 - 05/2007
3	Chronic Renal Insufficiency 02/2022 - 12/2015
3	Dysbiosis 01/2022 - 12/2017
3	Arthralgia (Joint Pain) 01/2022 - 12/2019
3	Pyoderma Gangrenosum 07/2021 - 01/2012
3	Uveitis 01/2021 - 01/2012

Drug/Important Bio-Agent (IBA)

63	Infliximab (Remicade)FDA Link 06/2022 - 11/2006
41	Biological ProductsIBA 01/2022 - 03/2006
35	Adalimumab (Humira)FDA Link 01/2022 - 04/2007
32	Pharmaceutical PreparationsIBA 12/2022 - 01/2012
31	vedolizumabIBA 12/2022 - 02/2014
31	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 06/2008
21	tofacitinibIBA 01/2022 - 05/2013
20	Ustekinumab (CNTO 1275)FDA Link 12/2022 - 03/2015
19	Biosimilar PharmaceuticalsIBA 01/2021 - 01/2015
18	Leukocyte L1 Antigen Complex (Calgranulin)IBA 10/2022 - 09/2013
16	Tumor Necrosis Factor InhibitorsIBA 01/2022 - 06/2008
16	SteroidsIBA 01/2022 - 06/2011
15	C-Reactive ProteinIBA 12/2022 - 12/2010
15	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2014
15	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 02/2010
14	Mesalamine (Mesalazine)FDA LinkGeneric 01/2021 - 01/2013
13	Azathioprine (Imuran)FDA LinkGeneric 07/2022 - 12/2008
13	Immunologic Factors (Immunomodulators)IBA 01/2021 - 02/2010
12	Immunosuppressive Agents (Immunosuppressants)IBA 01/2022 - 07/2013
12	Monoclonal AntibodiesIBA 01/2022 - 01/2011
12	2-mercaptopurineIBA 12/2020 - 06/2011
11	CytokinesIBA 10/2022 - 02/2011
11	Janus Kinase InhibitorsIBA 06/2022 - 11/2013
9	Phenobarbital (Luminal)FDA Link 11/2018 - 06/2008
8	Folic Acid (Vitamin M)FDA LinkGeneric 10/2020 - 06/2004
7	VaccinesIBA 01/2022 - 04/2011
7	AntibodiesIBA 01/2022 - 08/2013
7	Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric 10/2020 - 05/2007
6	Budesonide (Pulmicort)FDA LinkGeneric 12/2022 - 02/2014
6	IronIBA 10/2022 - 12/2015
6	Capsules (Microcapsules)IBA 09/2021 - 06/2005
6	golimumab FDA Link 01/2021 - 02/2014
5	Transferrin (beta 2 Transferrin)IBA 10/2022 - 02/2016
5	Ferritins (Ferritin)IBA 10/2022 - 02/2016
5	IntegrinsIBA 07/2022 - 11/2016
5	InterleukinsIBA 07/2022 - 01/2020
5	Janus KinasesIBA 06/2022 - 11/2013
5	upadacitinibIBA 01/2022 - 01/2020
5	NucleotidesIBA 07/2021 - 12/2008
5	etrasimodIBA 06/2021 - 05/2017
5	Dextrans (Dextran)FDA Link 10/2020 - 11/2011
5	Thioguanine (Tioguanine)FDA Link 07/2020 - 12/2008
4	Interleukin-23 (Interleukin 23)IBA 11/2022 - 01/2019
4	Mercaptopurine (6 Mercaptopurine)FDA LinkGeneric 08/2022 - 08/2009
4	GLPG0634IBA 06/2022 - 08/2017
4	Interleukin-17 (Interleukin 17)IBA 02/2022 - 01/2019
4	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 01/2021 - 05/2017
4	Proteins (Proteins, Gene)FDA Link 11/2019 - 06/2011
4	Methotrexate (Mexate)FDA LinkGeneric 03/2018 - 12/2010
4	HomocysteineIBA 08/2008 - 05/2007
3	CT-P13IBA 01/2022 - 01/2018
3	Janus Kinase 1IBA 01/2021 - 01/2020
3	sodium sulfate (sodium bisulfate)FDA LinkGeneric 10/2020 - 01/2017
3	Interleukin-12 (IL 12)IBA 01/2020 - 01/2019

Therapy/Procedure

145	Therapeutics 12/2022 - 11/2006
21	Biological Therapy 12/2022 - 04/2011
15	Colectomy 11/2022 - 02/2008
5	Remission Induction 01/2022 - 07/2015
4	Aftercare (After-Treatment) 11/2020 - 01/2019
3	Restorative Proctocolectomy 11/2022 - 03/2018
3	Ileostomy 11/2022 - 01/2012
3	Precision Medicine 12/2021 - 01/2018